US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Aridis Pharmaceuticals Inc.

0.0017

0.0000

Volume:- -

Turnover:- -

Market Cap:73.55K

PE:-0.04

High:0.0017

Open:0.0017

Low:0.0017

Close:0.0017

52wk High:0.0500

52wk Low:0.0000

Shares:44.57M

Float Shares:37.96M

Volume Ratio:- -

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.0399

EPS(LYR):-1.6174

ROE:415.66%

ROA:-4.40%

PB:-0.01

PE(LYR):0.00

Loading ...

Overview Company News Filings

MiNK Therapeutics Reports New Data on agenT-797, an allo-iNKT Cell Therapy at ATS 2026; Simultaneously Published in Clinical Immunology Communications

Edesa Biotech to Present New Data on Paridiprubart in Acute Kidney Injury at European Nephrology Conference

MiNK Therapeutics and First Lviv Territorial Medical Union Initiate Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury and Critical Illness

Press Release: Talphera Announces First Quarter 2026 Financial Results and Provides Corporate Update

MiNK Therapeutics Presents Clinical Evidence That a Single, Off-the-Shelf, iNKT Cell Product Drives Context-Dependent Immune Responses at ASGCT 2026

FibroBiologics Advancing Development of a Fibroblast Treatment for Hantavirus

Bayer’s ARDS ICU Study Shines Light on Long-Term Risks and Costs

MiNK Therapeutics: Buy Rating on Emerging Pulmonary Franchise and Key agenT-797 ARDS Catalyst

Edesa Biotech to Showcase Positive ARDS Phase 3 Data at ATS 2026 Summit

Edesa Biotech Invited for Oral Showcase at Respiratory Innovation Summit

Press Release: Talphera Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

China CDC Issues Health Protection Guidelines for February 2026 Spring Festival Holiday

Healios Launches Japan Arm of Global Phase 3 Trial for ARDS Stem Cell Therapy

Healios Files Japan Trial Plan for Global Phase 3 ARDS Stem Cell Study

InflaRx Plans Workforce Reduction, Targets Mid-2027 Cash Runway

Benzinga_recent_news

XORTX Announces Pioneering Research on Genome-Wide Pathogenic Pathways in Gout and Provides a Corporate Update

MediciNova Announces Completion of Patient Enrollment Evaluating MN-166 (ibudilast) in the Prevention of Chemotherapy-induced Peripheral Neuropathy

Healios Prioritizes ARDS Clinical Trials Over Stroke Lead Drug HLCM051

MT Newswires Live

MediciNova Announces Update and Basic Characteristic Randomized Patients’ of Phase 2/3 Clinical Trial of MN-166 (Ibudilast) in ALS (COMBAT-ALS Clinical Trial) Presented at the 36th International Symposium on ALS/MND

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ARDS/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ARDS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ARDS\",,,,,undefined,":{"symbol":"ARDS","market":"US","secType":"STK","nameCN":"Aridis Pharmaceuticals Inc.","latestPrice":0.00165,"timestamp":1779815700000,"preClose":0.00165,"halted":0,"volume":0,"delay":15,"changeRate":0,"floatShares":37958700,"shares":44574000,"eps":-0.039914,"marketStatus":"Trading","change":0,"latestTime":"05-26 13:15:00 EDT Delay","open":0.00165,"high":0.00165,"low":0.00165,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":-0.039914,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1779825600000},"marketStatusCode":2,"adr":0,"exchange":"EXPERT","adjPreClose":0.00165,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ARDS\",,,,,undefined,":{"symbol":"ARDS","floatShares":37958700,"roa":"-4.40%","roe":"415.66%","lyrEps":-1.617428,"shares":44574000,"dividePrice":0,"high":0.00165,"amplitude":0,"preClose":0.00165,"low":0.00165,"week52Low":0.000001,"pbRate":"-0.01","psRate":"0.00","week52High":0.05,"institutionHeld":0,"latestPrice":0.00165,"eps":-0.039914,"divideRate":0,"volume":0,"delay":15,"ttmEps":-0.039914,"open":0.00165,"prevYearClose":0.0015,"prevWeekClose":0.0016,"prevMonthClose":0.0002,"prevQuarterClose":0.0002,"fiveDayClose":0.0028,"twentyDayClose":0.0002,"sixtyDayClose":0.0018},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ARDS\",params:#limit:5,,,undefined,":[{"market":"US","date":"2023-11-03","symbol":"ARDS","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1698984000000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2023-07-19","symbol":"ARDS","reason":null,"defaultRemindTime":1689773400000,"announcedDate":"2023-07-18","type":"delisting","dateTimestamp":1689739200000},{"market":"US","date":"2023-06-08","symbol":"ARDS","fiscalQuarterEnding":"2023/03","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1686196800000,"reportTimeType":"post","actualEps":-0.22},{"market":"US","date":"2023-05-22","symbol":"ARDS","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1684728000000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2022-11-21","symbol":"ARDS","fiscalQuarterEnding":"2022/09","expectedEps":-0.01,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1669006800000,"reportTimeType":"post","actualEps":-0.42}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ARDS\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ARDS\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ARDS\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ARDS","date":"2023-07-17","current":-0.392816,"percent":0.924757,"low":-5.587062,"twenty":-3.267676,"median":-2.120819,"eighty":-0.574899,"high":-0.179871,"avg":-2.082391,"sd":1.334232,"marketCap":11557032},"quantilePoints":[{"date":"2021-05-28","current":-2.857671,"twenty":-3.600447,"median":-2.893886,"eighty":-2.017321,"marketCap":64926283},{"date":"2021-06-04","current":-2.981273,"twenty":-3.598105,"median":-2.893886,"eighty":-2.019714,"marketCap":67734513},{"date":"2021-06-11","current":-3.426239,"twenty":-3.588377,"median":-2.905456,"eighty":-2.022351,"marketCap":77844142},{"date":"2021-06-18","current":-3.282861,"twenty":-3.586939,"median":-2.907332,"eighty":-2.023325,"marketCap":74586595},{"date":"2021-06-25","current":-3.584449,"twenty":-3.586861,"median":-2.916417,"eighty":-2.023381,"marketCap":81438677},{"date":"2021-07-02","current":-3.702711,"twenty":-3.598105,"median":-2.923681,"eighty":-2.023902,"marketCap":84125591},{"date":"2021-07-09","current":-3.5622,"twenty":-3.600447,"median":-2.931832,"eighty":-2.025098,"marketCap":80933195},{"date":"2021-07-16","current":-2.892279,"twenty":-3.600447,"median":-2.929571,"eighty":-2.029338,"marketCap":65712587},{"date":"2021-07-23","current":-2.556083,"twenty":-3.588737,"median":-2.92228,"eighty":-2.031081,"marketCap":58074201},{"date":"2021-07-30","current":-2.46709,"twenty":-3.586939,"median":-2.914146,"eighty":-2.032344,"marketCap":56052275},{"date":"2021-08-06","current":-2.598017,"twenty":-3.586939,"median":-2.907332,"eighty":-2.054144,"marketCap":59026951},{"date":"2021-08-13","current":-2.255441,"twenty":-3.586548,"median":-2.899664,"eighty":-2.062408,"marketCap":54108038},{"date":"2021-08-20","current":-2.103126,"twenty":-3.584449,"median":-2.893886,"eighty":-2.062408,"marketCap":50453989},{"date":"2021-08-27","current":-2.208575,"twenty":-3.569617,"median":-2.892968,"eighty":-2.065174,"marketCap":52983715},{"date":"2021-09-03","current":-2.43119,"twenty":-3.569617,"median":-2.892101,"eighty":-2.066976,"marketCap":58324249},{"date":"2021-09-10","current":-2.314024,"twenty":-3.565712,"median":-2.890814,"eighty":-2.068132,"marketCap":55513442},{"date":"2021-09-17","current":-2.355032,"twenty":-3.563302,"median":-2.882246,"eighty":-2.073231,"marketCap":56497224},{"date":"2021-09-24","current":-2.232008,"twenty":-3.562349,"median":-2.875731,"eighty":-2.074819,"marketCap":53545877},{"date":"2021-10-01","current":-2.108984,"twenty":-3.561625,"median":-2.869864,"eighty":-2.078737,"marketCap":50594529},{"date":"2021-10-08","current":-1.991818,"twenty":-3.56,"median":-2.866447,"eighty":-2.066616,"marketCap":47783722},{"date":"2021-10-15","current":-2.062118,"twenty":-3.55628,"median":-2.852727,"eighty":-2.064621,"marketCap":49470206},{"date":"2021-10-22","current":-1.927377,"twenty":-3.552936,"median":-2.851863,"eighty":-2.060946,"marketCap":46237778},{"date":"2021-10-29","current":-2.050401,"twenty":-3.54501,"median":-2.848637,"eighty":-2.049229,"marketCap":49189126},{"date":"2021-11-05","current":-1.892227,"twenty":-3.540045,"median":-2.839191,"eighty":-2.037417,"marketCap":45394536},{"date":"2021-11-12","current":-1.039553,"twenty":-3.535858,"median":-2.83344,"eighty":-2.024799,"marketCap":40756704},{"date":"2021-11-19","current":-0.842396,"twenty":-3.535008,"median":-2.816655,"eighty":-2.021908,"marketCap":33026984},{"date":"2021-11-26","current":-0.856735,"twenty":-3.529087,"median":-2.806362,"eighty":-2.017919,"marketCap":33589146},{"date":"2021-12-03","current":-0.742026,"twenty":-3.524237,"median":-2.800578,"eighty":-2.010537,"marketCap":29091854},{"date":"2021-12-10","current":-0.820888,"twenty":-3.515406,"median":-2.793326,"eighty":-2.002588,"marketCap":32183742},{"date":"2021-12-17","current":-0.774288,"twenty":-3.509232,"median":-2.78446,"eighty":-1.992834,"marketCap":30356717},{"date":"2021-12-23","current":-0.946351,"twenty":-3.508124,"median":-2.773287,"eighty":-1.987272,"marketCap":37102655},{"date":"2021-12-31","current":-0.835227,"twenty":-3.507078,"median":-2.763568,"eighty":-1.971255,"marketCap":32745903},{"date":"2022-01-07","current":-0.616562,"twenty":-3.506856,"median":-2.759694,"eighty":-1.957517,"marketCap":24172941},{"date":"2022-01-14","current":-0.552038,"twenty":-3.501539,"median":-2.748337,"eighty":-1.935537,"marketCap":21643215},{"date":"2022-01-21","current":-0.573546,"twenty":-3.493391,"median":-2.733735,"eighty":-1.92659,"marketCap":22486457},{"date":"2022-01-28","current":-0.702594,"twenty":-3.491382,"median":-2.729679,"eighty":-1.918927,"marketCap":27545910},{"date":"2022-02-04","current":-0.85315,"twenty":-3.4899,"median":-2.718838,"eighty":-1.906174,"marketCap":33448605},{"date":"2022-02-11","current":-0.921259,"twenty":-3.487888,"median":-2.698489,"eighty":-1.890838,"marketCap":36118872},{"date":"2022-02-18","current":-0.777872,"twenty":-3.484012,"median":-2.681593,"eighty":-1.857586,"marketCap":30497258},{"date":"2022-02-25","current":-0.777872,"twenty":-3.483074,"median":-2.676975,"eighty":-1.851959,"marketCap":30497258},{"date":"2022-03-04","current":-0.63807,"twenty":-3.483074,"median":-2.665021,"eighty":-1.839639,"marketCap":25016184},{"date":"2022-03-11","current":-0.562792,"twenty":-3.479524,"median":-2.653689,"eighty":-1.833656,"marketCap":22064836},{"date":"2022-03-18","current":-0.587885,"twenty":-3.47762,"median":-2.644349,"eighty":-1.818918,"marketCap":23048619},{"date":"2022-03-25","current":-0.59147,"twenty":-3.477366,"median":-2.638047,"eighty":-1.809869,"marketCap":23189159},{"date":"2022-04-01","current":-0.566252,"twenty":-3.475679,"median":-2.616575,"eighty":-1.779813,"marketCap":23891861},{"date":"2022-04-08","current":-0.496303,"twenty":-3.465791,"median":-2.607105,"eighty":-1.773792,"marketCap":20940513},{"date":"2022-04-14","current":-0.604136,"twenty":-3.465415,"median":-2.602542,"eighty":-1.743755,"marketCap":25490292},{"date":"2022-04-22","current":-0.553791,"twenty":-3.462481,"median":-2.598017,"eighty":-1.725372,"marketCap":23366101},{"date":"2022-04-29","current":-0.524423,"twenty":-3.461698,"median":-2.585527,"eighty":-1.712043,"marketCap":22126990},{"date":"2022-05-06","current":-0.478274,"twenty":-3.457058,"median":-2.581707,"eighty":-1.700291,"marketCap":20179814},{"date":"2022-05-13","current":-0.39143,"twenty":-3.445523,"median":-2.570494,"eighty":-1.665546,"marketCap":16515585},{"date":"2022-05-20","current":-0.439786,"twenty":-3.440566,"median":-2.56819,"eighty":-1.645205,"marketCap":18940703},{"date":"2022-05-27","current":-0.452116,"twenty":-3.436897,"median":-2.558469,"eighty":-1.618092,"marketCap":19471751},{"date":"2022-06-03","current":-0.431566,"twenty":-3.433794,"median":-2.556083,"eighty":-1.598302,"marketCap":18586671},{"date":"2022-06-10","current":-0.600082,"twenty":-3.428639,"median":-2.553859,"eighty":-1.580133,"marketCap":25844324},{"date":"2022-06-17","current":-0.579531,"twenty":-3.421994,"median":-2.546545,"eighty":-1.56824,"marketCap":24959244},{"date":"2022-06-24","current":-0.513769,"twenty":-3.41313,"median":-2.540065,"eighty":-1.555467,"marketCap":22126990},{"date":"2022-07-01","current":-0.452116,"twenty":-3.400851,"median":-2.529007,"eighty":-1.539912,"marketCap":19471751},{"date":"2022-07-08","current":-0.505548,"twenty":-3.395701,"median":-2.523421,"eighty":-1.515025,"marketCap":21772958},{"date":"2022-07-15","current":-0.452116,"twenty":-3.393016,"median":-2.517718,"eighty":-1.495641,"marketCap":19471751},{"date":"2022-07-22","current":-0.460296,"twenty":-3.387105,"median":-2.515327,"eighty":-1.463335,"marketCap":19824012},{"date":"2022-07-29","current":-1.015207,"twenty":-3.385697,"median":-2.511586,"eighty":-1.408894,"marketCap":43722932},{"date":"2022-08-05","current":-0.920673,"twenty":-3.381415,"median":-2.506594,"eighty":-1.361051,"marketCap":39651566},{"date":"2022-08-12","current":-0.949445,"twenty":-3.379996,"median":-2.50282,"eighty":-1.359789,"marketCap":40890677},{"date":"2022-08-19","current":-0.68775,"twenty":-3.379213,"median":-2.487287,"eighty":-1.315925,"marketCap":31331817},{"date":"2022-08-26","current":-0.629466,"twenty":-3.377392,"median":-2.472034,"eighty":-1.259928,"marketCap":28676579},{"date":"2022-09-02","current":-0.586724,"twenty":-3.375179,"median":-2.468042,"eighty":-1.086252,"marketCap":26729403},{"date":"2022-09-09","current":-0.742148,"twenty":-3.374217,"median":-2.466333,"eighty":-1.015207,"marketCap":33810040},{"date":"2022-09-16","current":-0.664436,"twenty":-3.371854,"median":-2.461825,"eighty":-0.989367,"marketCap":30269722},{"date":"2022-09-23","current":-0.470157,"twenty":-3.365906,"median":-2.450968,"eighty":-0.946351,"marketCap":21418926},{"date":"2022-09-30","current":-0.36136,"twenty":-3.360417,"median":-2.439002,"eighty":-0.920673,"marketCap":16462480},{"date":"2022-10-07","current":-0.42807,"twenty":-3.357022,"median":-2.432056,"eighty":-0.90692,"marketCap":19501592},{"date":"2022-10-14","current":-0.41968,"twenty":-3.356667,"median":-2.428332,"eighty":-0.900123,"marketCap":19119360},{"date":"2022-10-21","current":-0.42807,"twenty":-3.355429,"median":-2.418104,"eighty":-0.878243,"marketCap":19501592},{"date":"2022-10-28","current":-0.418653,"twenty":-3.355255,"median":-2.405141,"eighty":-0.856735,"marketCap":19072556},{"date":"2022-11-04","current":-0.385263,"twenty":-3.352504,"median":-2.397513,"eighty":-0.835227,"marketCap":17551432},{"date":"2022-11-11","current":-0.355298,"twenty":-3.351704,"median":-2.387363,"eighty":-0.828058,"marketCap":16186321},{"date":"2022-11-18","current":-0.358423,"twenty":-3.351704,"median":-2.382754,"eighty":-0.817304,"marketCap":16328682},{"date":"2022-11-25","current":-0.570968,"twenty":-3.34872,"median":-2.372465,"eighty":-0.802965,"marketCap":18724320},{"date":"2022-12-02","current":-0.602688,"twenty":-3.345928,"median":-2.355032,"eighty":-0.788328,"marketCap":19764560},{"date":"2022-12-09","current":-0.729171,"twenty":-3.344766,"median":-2.343316,"eighty":-0.777872,"marketCap":23912448},{"date":"2022-12-16","current":-0.744363,"twenty":-3.344324,"median":-2.337457,"eighty":-0.777155,"marketCap":24410624},{"date":"2022-12-23","current":-0.78234,"twenty":-3.338852,"median":-2.321106,"eighty":-0.77286,"marketCap":25656064},{"date":"2022-12-30","current":-0.896273,"twenty":-3.337502,"median":-2.310151,"eighty":-0.767149,"marketCap":29392384},{"date":"2023-01-06","current":-1.040588,"twenty":-3.337502,"median":-2.304356,"eighty":-0.767149,"marketCap":34125056},{"date":"2023-01-13","current":-0.968431,"twenty":-3.337277,"median":-2.288331,"eighty":-0.770005,"marketCap":31758720},{"date":"2023-01-20","current":-0.896273,"twenty":-3.335635,"median":-2.284884,"eighty":-0.774288,"marketCap":29392384},{"date":"2023-01-27","current":-0.539207,"twenty":-3.330292,"median":-2.284733,"eighty":-0.767149,"marketCap":17682757},{"date":"2023-02-03","current":-0.522953,"twenty":-3.328325,"median":-2.278871,"eighty":-0.761383,"marketCap":17149708},{"date":"2023-02-10","current":-0.454897,"twenty":-3.321763,"median":-2.270384,"eighty":-0.75278,"marketCap":14917880},{"date":"2023-02-17","current":-0.455732,"twenty":-3.317149,"median":-2.266166,"eighty":-0.74688,"marketCap":14945280},{"date":"2023-02-24","current":-0.444491,"twenty":-3.309098,"median":-2.26141,"eighty":-0.742148,"marketCap":14576629},{"date":"2023-03-03","current":-0.397854,"twenty":-3.304161,"median":-2.253938,"eighty":-0.724102,"marketCap":13047229},{"date":"2023-03-10","current":-0.348863,"twenty":-3.302547,"median":-2.243725,"eighty":-0.716933,"marketCap":11440611},{"date":"2023-03-17","current":-0.409687,"twenty":-3.300826,"median":-2.228382,"eighty":-0.703292,"marketCap":13435272},{"date":"2023-03-24","current":-0.44005,"twenty":-3.30041,"median":-2.21654,"eighty":-0.695425,"marketCap":14431012},{"date":"2023-03-31","current":-0.34555,"twenty":-3.30041,"median":-2.214357,"eighty":-0.676093,"marketCap":11331952},{"date":"2023-04-06","current":-0.291753,"twenty":-3.29957,"median":-2.210892,"eighty":-0.664181,"marketCap":9567761},{"date":"2023-04-14","current":-0.253029,"twenty":-3.297412,"median":-2.208575,"eighty":-0.648107,"marketCap":8297832},{"date":"2023-04-21","current":-0.26293,"twenty":-3.296925,"median":-2.202343,"eighty":-0.63807,"marketCap":8622530},{"date":"2023-04-28","current":-0.208034,"twenty":-3.294155,"median":-2.191,"eighty":-0.630901,"marketCap":6822261},{"date":"2023-05-05","current":-0.198023,"twenty":-3.293462,"median":-2.183656,"eighty":-0.623732,"marketCap":6493955},{"date":"2023-05-12","current":-0.242028,"twenty":-3.292592,"median":-2.171452,"eighty":-0.616325,"marketCap":7937057},{"date":"2023-05-19","current":-0.224426,"twenty":-3.289772,"median":-2.160655,"eighty":-0.605474,"marketCap":7359816},{"date":"2023-05-26","current":-0.215128,"twenty":-3.284113,"median":-2.15585,"eighty":-0.602553,"marketCap":6533641},{"date":"2023-06-02","current":-0.338312,"twenty":-3.282139,"median":-2.149992,"eighty":-0.600025,"marketCap":10274881},{"date":"2023-06-09","current":-0.34335,"twenty":-3.279407,"median":-2.139426,"eighty":-0.591517,"marketCap":10101708},{"date":"2023-06-16","current":-0.330965,"twenty":-3.274532,"median":-2.132784,"eighty":-0.585754,"marketCap":9737325},{"date":"2023-06-23","current":-0.31576,"twenty":-3.271532,"median":-2.132417,"eighty":-0.583612,"marketCap":9289964},{"date":"2023-06-30","current":-0.268159,"twenty":-3.270406,"median":-2.131556,"eighty":-0.579531,"marketCap":7889513},{"date":"2023-07-07","current":-0.287006,"twenty":-3.270406,"median":-2.123811,"eighty":-0.577312,"marketCap":8443990},{"date":"2023-07-14","current":-0.432356,"twenty":-3.267931,"median":-2.121678,"eighty":-0.575421,"marketCap":12720346},{"date":"2023-07-17","current":-0.392816,"twenty":-3.267676,"median":-2.120819,"eighty":-0.574899,"marketCap":11557032}],"updateTime":1779801943328},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ARDS\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2636265708","title":"MiNK Therapeutics Reports New Data on agenT-797, an allo-iNKT Cell Therapy at ATS 2026; Simultaneously Published in Clinical Immunology Communications","url":"https://stock-news.laohu8.com/highlight/detail?id=2636265708","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636265708?lang=en_us&edition=fundamental","pubTime":"2026-05-20 23:07","pubTimestamp":1779289620,"startTime":"0","endTime":"0","summary":"agenT-797 demonstrates pathogen suppression, lung immune restoration and tissue repair activation, supporting Ongoing Phase 2 trialSequential immunotherapy with agenT-797 and N-803, an FDA-approved IL","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/20/3298712/0/en/MiNK-Therapeutics-Reports-New-Data-on-agenT-797-an-allo-iNKT-Cell-Therapy-at-ATS-2026-Simultaneously-Published-in-Clinical-Immunology-Communications.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4161","INKT","BK4139","ATS","ARDS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636851924","title":"Edesa Biotech to Present New Data on Paridiprubart in Acute Kidney Injury at European Nephrology Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2636851924","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636851924?lang=en_us&edition=fundamental","pubTime":"2026-05-19 21:15","pubTimestamp":1779196500,"startTime":"0","endTime":"0","summary":"Oral presentation at ERA Congress, the flagship European nephrology meetingCompany expects to present additional data  TORONTO, May  19, 2026  (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq: EDSA), a","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/19/3297637/0/en/Edesa-Biotech-to-Present-New-Data-on-Paridiprubart-in-Acute-Kidney-Injury-at-European-Nephrology-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARDS","BK4581","EPV","BK4588","EDSA","XBI","BK4585","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635714125","title":"MiNK Therapeutics and First Lviv Territorial Medical Union Initiate Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury and Critical Illness","url":"https://stock-news.laohu8.com/highlight/detail?id=2635714125","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635714125?lang=en_us&edition=fundamental","pubTime":"2026-05-14 19:30","pubTimestamp":1778758200,"startTime":"0","endTime":"0","summary":"Randomized Phase 2 trial evaluates off-the-shelf invariant natural killer T (iNKT) cell therapy in patients with acute lung injury and hypoxemic respiratory failureStudy initiates in Lviv, Ukraine, in","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/14/3294797/0/en/MiNK-Therapeutics-and-First-Lviv-Territorial-Medical-Union-Initiate-Randomized-Phase-2-Trial-of-agenT-797-in-Acute-Lung-Injury-and-Critical-Illness.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4195","INKT","BK4139","TBNK","BK4211","ARDS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635222758","title":"Press Release: Talphera Announces First Quarter 2026 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2635222758","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635222758?lang=en_us&edition=fundamental","pubTime":"2026-05-14 04:05","pubTimestamp":1778702700,"startTime":"0","endTime":"0","summary":"NEPHRO CRRT clinical study expected to be completed this year. Cash and investments of $21.1 million at March 31, 2026. Conference call and webcast to be held on Wednesday, May 13, 2026 at 4:30 pm ET. SAN MATEO, Calif., May 13, 2026 /PRNewswire/ -- Talphera, Inc. , , a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced first quarter 2026 financial results and provided a corporate update.-- In March 2026, announced reaching the 35-patient enrollment milestone,representing 50% enrollment in the NEPHRO CRRT study. Enrollment has. continued to increase since this announcement, with study completion. leaders  focused on anticoagulants used during CRRT and the. Study of the Safety and Efficacy of Niyad in Patients Undergoing. Continuous Renal Replacement Therapy Who Cannot Tolerate Heparin or Are. at a Higher Risk of Bleeding\" and, \"In Vivo Assessment of Nafamostat, A. Novel Regio","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4232","R","IDE","BK4022","BK4007","TLPH","ARDS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634373216","title":"MiNK Therapeutics Presents Clinical Evidence That a Single, Off-the-Shelf, iNKT Cell Product Drives Context-Dependent Immune Responses at ASGCT 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2634373216","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634373216?lang=en_us&edition=fundamental","pubTime":"2026-05-12 19:35","pubTimestamp":1778585700,"startTime":"0","endTime":"0","summary":"iNKT therapy, agenT-797, delivers context-dependent immune reprogramming showing activation in cancer and anti-inflammatory benefit in ARDS — from the same manufacturing donor batch, without genetic e","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/12/3292728/0/en/MiNK-Therapeutics-Presents-Clinical-Evidence-That-a-Single-Off-the-Shelf-iNKT-Cell-Product-Drives-Context-Dependent-Immune-Responses-at-ASGCT-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARDS","INKT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634928111","title":"FibroBiologics Advancing Development of a Fibroblast Treatment for Hantavirus","url":"https://stock-news.laohu8.com/highlight/detail?id=2634928111","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634928111?lang=en_us&edition=fundamental","pubTime":"2026-05-11 20:30","pubTimestamp":1778502600,"startTime":"0","endTime":"0","summary":"Will Apply Existing Preclinical Findings in Reducing Severe Immune-Mediated Lung Failure to Potential Emerging Global CrisisHOUSTON, May  11, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBL","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/11/3291882/0/en/FibroBiologics-Advancing-Development-of-a-Fibroblast-Treatment-for-Hantavirus.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HPS","FBLG","BK4139","ARDS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624685661","title":"Bayer’s ARDS ICU Study Shines Light on Long-Term Risks and Costs","url":"https://stock-news.laohu8.com/highlight/detail?id=2624685661","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624685661?lang=en_us&edition=fundamental","pubTime":"2026-04-03 00:30","pubTimestamp":1775147451,"startTime":"0","endTime":"0","summary":"Bayer AG ($BAYRY) announced an update on their ongoing clinical study. Bayer’s latest U.S. study, “Identifying Post ICU Morbidity in Patients With ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/bayers-ards-icu-study-shines-light-on-long-term-risks-and-costs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/bayers-ards-icu-study-shines-light-on-long-term-risks-and-costs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4082","ARDS","ICU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624594079","title":"MiNK Therapeutics: Buy Rating on Emerging Pulmonary Franchise and Key agenT-797 ARDS Catalyst","url":"https://stock-news.laohu8.com/highlight/detail?id=2624594079","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624594079?lang=en_us&edition=fundamental","pubTime":"2026-04-01 18:15","pubTimestamp":1775038526,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Emily Bodnar maintained a Buy rating on MiNK Therapeutics today and set a price target of $35.00. Emily Bodnar has given hi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/mink-therapeutics-buy-rating-on-emerging-pulmonary-franchise-and-key-agent-797-ards-catalyst-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/mink-therapeutics-buy-rating-on-emerging-pulmonary-franchise-and-key-agent-797-ards-catalyst-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ARDS","INKT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624155277","title":"Edesa Biotech to Showcase Positive ARDS Phase 3 Data at ATS 2026 Summit","url":"https://stock-news.laohu8.com/highlight/detail?id=2624155277","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624155277?lang=en_us&edition=fundamental","pubTime":"2026-04-01 08:39","pubTimestamp":1775003984,"startTime":"0","endTime":"0","summary":"Edesa Biotech ( ($EDSA) ) has provided an announcement. Edesa Biotech has been selected to deliver the inaugural Oral Showcase presentation at the ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/edesa-biotech-to-showcase-positive-ards-phase-3-data-at-ats-2026-summit?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/edesa-biotech-to-showcase-positive-ards-phase-3-data-at-ats-2026-summit?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4211","ATS","BK4581","EDSA","BK4161","BK4139","XBI","BK4588","SMMF","BK4585","ARDS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624305535","title":"Edesa Biotech Invited for Oral Showcase at Respiratory Innovation Summit","url":"https://stock-news.laohu8.com/highlight/detail?id=2624305535","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624305535?lang=en_us&edition=fundamental","pubTime":"2026-04-01 04:20","pubTimestamp":1774988400,"startTime":"0","endTime":"0","summary":"Selection Follows Positive Phase 3 Results for Paridiprubart Demonstrating Statistically Significant Mortality Reductions in ARDS PatientsTORONTO, March  31, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, In","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/31/3266063/0/en/Edesa-Biotech-Invited-for-Oral-Showcase-at-Respiratory-Innovation-Summit.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARDS","SMMF","XBI","BK4588","BK4161","BK4581","BK4139","BK4585","BK4211","EDSA","ATS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621589705","title":"Press Release: Talphera Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2621589705","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621589705?lang=en_us&edition=fundamental","pubTime":"2026-03-23 20:30","pubTimestamp":1774269000,"startTime":"0","endTime":"0","summary":"Previously announced achievement of 50% enrollment of the NEPHRO CRRT clinical study in March 2026 and closed the associated financing tranche of $4.1 million. All 12 clinical study sites now able to enroll patients to support an expected study completion in 2026. Cash and investments of $20.4 million at December 31, 2025. Virtual investor and analyst day with business updates to be held on Monday, March 23, 2026 at 11:00 am ET. SAN MATEO, Calif., March 23, 2026 /PRNewswire/ -- Talphera, Inc. , , a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced fourth quarter and full year 2025 financial results and provided a corporate update.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"8603dabb40994e59ac78c04c930c0d49","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4232","BK4007","R","TLPH","IDE","BK4022","BK4139","ARDS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142300209","title":"China CDC Issues Health Protection Guidelines for February 2026 Spring Festival Holiday","url":"https://stock-news.laohu8.com/highlight/detail?id=1142300209","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1142300209?lang=en_us&edition=fundamental","pubTime":"2026-02-09 15:16","pubTimestamp":1770621401,"startTime":"0","endTime":"0","summary":"With the Spring Festival holiday in February, increased travel, gatherings, domestic tourism, and outbound travel are expected. The Chinese Center for Disease Control and Prevention reminds the...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARDS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608825734","title":"Healios Launches Japan Arm of Global Phase 3 Trial for ARDS Stem Cell Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2608825734","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608825734?lang=en_us&edition=fundamental","pubTime":"2026-02-03 16:23","pubTimestamp":1770106982,"startTime":"0","endTime":"0","summary":"An update from Healios KK ( ($JP:4593) ) is now available. Healios K.K. has begun preparations to initiate patient enrollment in Japan for the glob...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/healios-launches-japan-arm-of-global-phase-3-trial-for-ards-stem-cell-therapy?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/healios-launches-japan-arm-of-global-phase-3-trial-for-ards-stem-cell-therapy?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ARDS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2604162860","title":"Healios Files Japan Trial Plan for Global Phase 3 ARDS Stem Cell Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2604162860","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604162860?lang=en_us&edition=fundamental","pubTime":"2026-01-20 14:57","pubTimestamp":1768892252,"startTime":"0","endTime":"0","summary":"Healios KK ( ($JP:4593) ) has shared an announcement. Healios K.K. has submitted a clinical trial plan notification to Japan’s Pharmaceuticals and ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/healios-files-japan-trial-plan-for-global-phase-3-ards-stem-cell-study?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/healios-files-japan-trial-plan-for-global-phase-3-ards-stem-cell-study?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ARDS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2602734391","title":"InflaRx Plans Workforce Reduction, Targets Mid-2027 Cash Runway","url":"https://stock-news.laohu8.com/highlight/detail?id=2602734391","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602734391?lang=en_us&edition=fundamental","pubTime":"2026-01-09 01:22","pubTimestamp":1767892920,"startTime":"0","endTime":"0","summary":"InflaRx outlines restructuring plans, workforce cuts, and reduced Gohibic spending to extend cash runway and focus development efforts on izicopan through mid-2027.","market":"sh","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/01/08/biotech-lab.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/01/08/biotech-lab.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/health-care/26/01/49791962/inflarx-plans-workforce-reduction-targets-mid-2027-cash-runway","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/health-care/26/01/49791962/inflarx-plans-workforce-reduction-targets-mid-2027-cash-runway","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["IFRX","BK4139","ARDS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2600702479","title":"XORTX Announces Pioneering Research on Genome-Wide Pathogenic Pathways in Gout and Provides a Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2600702479","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600702479?lang=en_us&edition=fundamental","pubTime":"2026-01-01 07:15","pubTimestamp":1767222900,"startTime":"0","endTime":"0","summary":"Clinical Data doubles known genetic factors associated with urate and GoutCALGARY, Alberta, Dec.  31, 2025  (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (\"XORTX\" or the “Company”) (NASDAQ: XRTX | TSXV:","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/31/3211946/0/en/XORTX-Announces-Pioneering-Research-on-Genome-Wide-Pathogenic-Pathways-in-Gout-and-Provides-a-Corporate-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","CORD","ARDS","XRTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2592651970","title":"MediciNova Announces Completion of Patient Enrollment Evaluating MN-166 (ibudilast) in the Prevention of Chemotherapy-induced Peripheral Neuropathy","url":"https://stock-news.laohu8.com/highlight/detail?id=2592651970","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592651970?lang=en_us&edition=fundamental","pubTime":"2025-12-18 19:00","pubTimestamp":1766055600,"startTime":"0","endTime":"0","summary":"LA JOLLA, Calif., Dec.  18, 2025  (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/18/3207535/7767/en/MediciNova-Announces-Completion-of-Patient-Enrollment-Evaluating-MN-166-ibudilast-in-the-Prevention-of-Chemotherapy-induced-Peripheral-Neuropathy.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0557290698.USD","LU1989772923.USD","LU1720051108.HKD","LU2089284900.SGD","LU0106261372.USD","LU0267386448.USD","LU0158827948.USD","LU0320765646.SGD","LU1363072403.SGD","BK4588","LU1548497426.USD","LU2023251221.USD","LU0225283273.USD","LU1720051017.SGD","BK4534","LU1791710582.SGD","LU2111349929.HKD","LU0795875086.SGD","LU2357305700.SGD","ARDS","BK4516","LU0234570918.USD","LU1244550494.USD","BK4139","LU0314104364.USD","IE00BKVL7J92.USD","LU0158827781.USD","LU2089283258.USD","LU0098860793.USD","LU1791710400.SGD","MNOV","LU0971096721.USD","LU1074936037.SGD","LU2271345857.HKD","LU1732799900.SGD","BK4127","LU1668664300.SGD","LU0106831901.USD","BK4504","LU0795875169.SGD","BK4585","LU2133065610.SGD","LU1244550577.SGD","LU0528227936.USD","LU0882574139.USD","IE00BZ1G4Q59.USD","LU1989772840.SGD","LU1244550221.USD","LU0912757837.SGD","LU1732800096.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2590312566","title":"Healios Prioritizes ARDS Clinical Trials Over Stroke Lead Drug HLCM051","url":"https://stock-news.laohu8.com/highlight/detail?id=2590312566","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590312566?lang=en_us&edition=fundamental","pubTime":"2025-12-09 18:00","pubTimestamp":1765274449,"startTime":"0","endTime":"0","summary":"Healios will submit a clinical trial application for a global Phase 3 Acute Respiratory Distress Syndrome  study in early 2026, according to its Tokyo bourse filing on Tuesday.The group said this after shifting its development strategy for the regenerative medicine HLCM051 , now prioritizing its advancement as a treatment for ARDS in the near term.Concurrently, Healios has decided not to pursue a rolling submission for conditional approval of HLCM051 for ischemic stroke by the end of 2025 or early 2026, citing ongoing regulatory discussions and the need to allocate resources effectively.The company will continue its dialogue with regulators to reevaluate the stroke program's development path at a later date.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ARDS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2589342853","title":"MediciNova Announces Update and Basic Characteristic Randomized Patients’ of Phase 2/3 Clinical Trial of MN-166 (Ibudilast) in ALS (COMBAT-ALS Clinical Trial) Presented at the 36th International Symposium on ALS/MND","url":"https://stock-news.laohu8.com/highlight/detail?id=2589342853","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589342853?lang=en_us&edition=fundamental","pubTime":"2025-12-08 19:00","pubTimestamp":1765191600,"startTime":"0","endTime":"0","summary":"LA JOLLA, Calif., Dec.  08, 2025  (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company listed on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchang","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/08/3201345/7767/en/MediciNova-Announces-Update-and-Basic-Characteristic-Randomized-Patients-of-Phase-2-3-Clinical-Trial-of-MN-166-Ibudilast-in-ALS-COMBAT-ALS-Clinical-Trial-Presented-at-the-36th-Inte.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4516","LU0795875169.SGD","LU1074936037.SGD","LU2271345857.HKD","ARDS","BK4127","LU0267386448.USD","LU1162221912.USD","LU0882574139.USD","BK4588","LU1548497426.USD","LU1720051017.SGD","LU2111349929.HKD","LU1791710582.SGD","IE00BKVL7J92.USD","MNOV","LU0912757837.SGD","LU1732800096.USD","LU2028103732.USD","BK4534","LU0106261372.USD","LU0106831901.USD","IE00BZ1G4Q59.USD","LU0234570918.USD","LU0557290698.USD","BK4585","LU1363072403.SGD","LU0158827948.USD","LU2089284900.SGD","LU0528227936.USD","LU0225283273.USD","LU1989772923.USD","BK4581","LU0320765646.SGD","LU1732799900.SGD","LU0098860793.USD","LU1244550221.USD","LU0158827781.USD","LU2357305700.SGD","LU2347655156.SGD","LU0971096721.USD","LU0314104364.USD","LU2023251221.USD","LU0006306889.USD","LU2133065610.SGD","LU1791710400.SGD","LU1989772840.SGD","LU0795875086.SGD","BK4504","LU1720051108.HKD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":19,"code":"91000000","status":"200"}]}}